Modulation of lipid and protein mediators of inflammation by cytosolic phospholipase A2α during experimental sepsis

Journal of Immunology

Volumn 181, Issue 5, 2008, Pages 3558-3566

  Uozumi, Naonori ^a,b   Kita, Yoshihiro ^a   Shimizu, Takao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2 ALPHA; ENZYME; ICOSANOID; INTERLEUKIN 6; LEUKOTRIENE B4; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; CYTOKINE; LIPID; PHOSPHOLIPASE A2 GROUP IV; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CECUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE DISRUPTION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PERITONEUM LAVAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PUNCTURE; SEPSIS; SURVIVAL; TRANSGENIC MOUSE; WEIGHT REDUCTION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; ENZYMOLOGY; IMMUNOLOGY; MOUSE MUTANT; PHENOTYPE; PHYSIOLOGY; SURVIVAL RATE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; EICOSANOIDS; GROUP IV PHOSPHOLIPASES A2; INFLAMMATION; LIPIDS; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE; PROTEINS; SEPSIS; SURVIVAL RATE;

EID: 51549112055     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.5.3558     Document Type: Article

References (83)

1. Levy, M. M., M. P. Fink, J. C. Marshall, E. Abraham, D. Angus, D. Cook, J. Cohen, S. M. Opal, J. L. Vincent, and G. Ramsay. 2003. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31: 1250-1256. (Pubitemid 36444440)
2. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554. (Pubitemid 36437931)
3. Moss, M., and G. S. Martin. 2004. A global perspective on the epidemiology of sepsis. Int. Care Med. 30: 527-529.
4. Riedemann, N. C., R. F. Guo, and P. A. Ward. 2003. The enigma of sepsis. J. Clin. Invest. 112: 460-467.
5. Annane, D., E. Bellissant, and J. M. Cavaillon. 2005. Septic shock. Lancet 365: 63-78.
6. Baron, R. M., M. J. Baron, and M. A. Perrella. 2006. Pathobiology of sepsis: are we still asking the same questions? Am. J. Respir. Cell Mol. Biol. 34: 129-134.
7. Hubbard, W. J., M. Choudhry, M. G. Schwacha, J. D. Kerby, L. W. Rue III, K. I. Bland, and I. H. Chaudry. 2005. Cecal ligation and puncture. Shock 24 (Suppl. 1): 52-57.
8. Remick, D. G., and P. A. Ward. 2005. Evaluation of endotoxin models for the study of sepsis. Shock 24 (Suppl. 1): 7-11. (Pubitemid 43756012)
9. Xiao, H., J. Siddiqui, and D. G. Remick. 2006. Mechanisms of mortality in early and late sepsis. Infect. Immun. 74: 5227-5235. (Pubitemid 44300441)
10. Funk, C. D. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875.
11. Samuelsson, B. 1983. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568-575. (Pubitemid 13130140)
12. Grosser, T., S. Fries, and G. A. FitzGerald. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116: 4-15. (Pubitemid 43121782)
13. Narumiya, S., Y. Sugimoto, and F. Ushikubi. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79: 1193-1226. (Pubitemid 29473315)
14. Arm, J. P. 2004. Leukotriene generation and clinical implications. Allergy Asthma Proc. 25: 37-42.
15. Brink, C., S. E. Dahlen, J. Drazen, J. F. Evans, D. W. Hay, S. Nicosia, C. N. Serhan, T. Shimizu, and T. Yokomizo. 2003. International Union of Pharmacology XXXVII: nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55: 195-227. (Pubitemid 36268403)
16. Schaloske, R. H., and E. A. Dennis. 2006. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 1761: 1246-1259.
17. 2. Biol. Pharm. Bull. 27: 1158-1164.
18. 2 family. Prog. Lipid Res. 45: 487-510.
19. Kita, Y., T. Ohto, N. Uozumi, and T. Shimizu. 2006. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim. Biophys. Acta 1761: 1317-1322. (Pubitemid 44738706)
20. 2 in allergic response and parturition. Nature 390: 618-622.
21. 2. Nature 390: 622-625.
22. Sapirstein, A., and J. V. Bonventre. 2000. Specific physiological roles of cytosolic phospholipase A2 as defined by gene knockouts. Biochim. Biophys. Acta 1448: 139-148. (Pubitemid 30842586)
23. 2α as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat. 69: 59-69.
24. 2. Nat. Immunol. 1: 42-46.
25. 2 in bleomycininduced pulmonary fibrosis. Nat. Med. 8: 480-484.
26. 2. J. Exp. Med. 196: 349-357.
27. 2α-deficient mice are resistant to collagen-induced arthritis. J. Exp. Med. 197: 1297-1302.
28. 2α in prostaglandin E2-mediated bone resorption associated with inflammation. J. Exp. Med. 197: 1303-1310.
29. 2α-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med. 202: 841-851.
30. 2 gene. J. Biol. Chem. 275: 34013-34016.
31. 2α in autoimmune diabetes of mice. FEBS Lett. 579: 3975-3978.
32. Benjamim, C. F., C. Canetti, F. Q. Cunha, S. L. Kunkel, and M. Peters-Golden. 2005. Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J. Immunol. 174: 1616-1620.
33. Kita, Y., T. Takahashi, N. Uozumi, and T. Shimizu. 2005. A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatography-tandem mass spectrometry. Anal. Biochem. 342: 134-143. (Pubitemid 40805637)
34. Remick, D. G., G. R. Bolgos, J. Siddiqui, J. Shin, and J. A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463-467.
35. Cheng, Y., S. C. Austin, B. Rocca, B. H. Koller, T. M. Coffman, T. Grosser, J. A. Lawson, and G. A. FitzGerald. 2002. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541. (Pubitemid 34408674)
36. Hayaishi, O., and Y. Urade. 2002. Prostaglandin D2 in sleep-wake regulation: recent progress and perspectives. Neuroscientist 8: 12-15. (Pubitemid 34101813)
37. Drazen, J. M. 2003. Leukotrienes in asthma. Adv. Exp. Med. Biol. 525: 1-5.
38. 4: novel interactions in the persistence and progression of asthma. J. Allergy Clin. Immunol. 117: 577-582.
39. Tilley, S. L., T. M. Coffman, and B. H. Koller. 2001. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108: 15-23.
40. Narumiya, S. 2003. Prostanoids in immunity: roles revealed by mice deficient in their receptors. Life Sci. 74: 391-395. (Pubitemid 37357068)
41. Kunikata, T., H. Yamane, E. Segi, T. Matsuoka, Y. Sugimoto, S. Tanaka, H. Tanaka, H. Nagai, A. Ichikawa, and S. Narumiya. 2005. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat. Immunol. 6: 524-531. (Pubitemid 41716766)
42. Moore, B. B., M. J. Coffey, P. Christensen, S. Sitterding, R. Ngan, C. A. Wilke, R. McDonald, S. M. Phare, M. Peters-Golden, R. Paine III, and G. B. Toews. 2000. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin- dependent mechanism. J. Immunol. 165: 4032-4039.
43. 2 production. Am. J. Pathol. 165: 1663-1676.
44. Lovgren, A. K., L. A. Jania, J. M. Hartney, K. K. Parsons, L. P. Audoly, G. A. Fitzgerald, S. L. Tilley, and B. H. Koller. 2006. COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am. J. Physiol. 291: L144-L156.
45. Peters-Golden, M., M. Bailie, T. Marshall, C. Wilke, S. H. Phan, G. B. Toews, and B. B. Moore. 2002. Protection from pulmonary fibrosis in leukotriene-defi- cient mice. Am. J. Respir. Crit. Care Med. 165: 229-235. (Pubitemid 34084463)
46. Beller, T. C., D. S. Friend, A. Maekawa, B. K. Lam, K. F. Austen, and Y. Kanaoka. 2004. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl. Acad. Sci. USA 101: 3047-3052.
47. Beller, T. C., A. Maekawa, D. S. Friend, K. F. Austen, and Y. Kanaoka. 2004. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J. Biol. Chem. 279: 46129-46134.
48. 4 receptor (BLT-1) modulates neutrophil influx into the peritoneum but not the lung and liver during surgically induced bacterial peritonitis in mice. Clin. Diagn. Lab. Immunol. 11: 936-941.
49. 2 regulation. J. Biol. Chem. 275: 20146-20156.
50. 2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. Proc. Natl. Acad. Sci. USA 96: 4803-4807.
51. 2 in the production of lipid mediators and histamine release in mouse bone-marrow-derived mast cells. Biochem. J. 352: 311-317.
52. Reddy, R. C., G. H. Chen, K. Tateda, W. C. Tsai, S. M. Phare, P. Mancuso, M. Peters-Golden, and T. J. Standiford. 2001. Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am. J. Physiol. 281: L537-L543. (Pubitemid 32879204)
53. Chiang, N., C. N. Serhan, S. E. Dahlen, J. M. Drazen, D. W. Hay, G. E. Rovati, T. Shimizu, T. Yokomizo, and C. Brink. 2006. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58: 463-487. (Pubitemid 44394909)
54. 4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12: 330-334.
55. Karp, C. L., L. M. Flick, K. W. Park, S. Softic, T. M. Greer, R. Keledjian, R. Yang, J. Uddin, W. B. Guggino, S. F. Atabani, et al. 2004. Defective lipoxinmediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5: 388-392.
56. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
57. Peters-Golden, M., C. Canetti, P. Mancuso, and M. J. Coffey. 2005. Leukotrienes: underappreciated mediators of innate immune responses. J. Immunol. 174: 589-594. (Pubitemid 40103563)
58. 4. J. Immunol. 163: 6148-6154.
59. Matsukawa, A., C. M. Hogaboam, N. W. Lukacs, P. M. Lincoln, R. M. Strieter, and S. L. Kunkel. 2000. Endogenous MCP-1 influences systemic cytokine balance in a murine model of acute septic peritonitis. Exp. Mol. Pathol. 68: 77-84. (Pubitemid 30170034)
60. Speyer, C. L., H. Gao, N. J. Rancilio, T. A. Neff, G. B. Huffnagle, J. V. Sarma, and P. A. Ward. 2004. Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am. J. Pathol. 165: 2187-2196.
61. Gomes, R. N., R. T. Figueiredo, F. A. Bozza, P. Pacheco, R. T. Amancio, A. P. Laranjeira, H. C. Castro-Faria-Neto, P. T. Bozza, and M. T. Bozza. 2006. Increased susceptibility to septic and endotoxic shock in monocyte chemoattractant protein 1/CC chemokine ligand 2-deficient mice correlates with reduced interleukin 10 and enhanced macrophage migration inhibitory factor production. Shock 26: 457-463.
62. Brach, M. A., S. de Vos, C. Arnold, H. J. Gruss, R. Mertelsmann, and F. Herrmann. 1992. Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK-κB and NF-IL6. Eur. J. Immunol. 22: 2705-2711.
63. 4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler. Thromb. Vasc. Biol. 24: 1783-1788.
64. Echtenacher, B., D. N. Mannel, and L. Hultner. 1996. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381: 75-77. (Pubitemid 26130005)
65. Rouzer, C. A., P. J. Kingsley, H. Wang, H. Zhang, J. D. Morrow, S. K. Dey, and L. J. Marnett. 2004. Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-αsecretion in lipopolysaccharide- challenged murine resident peritoneal macrophages. J. Biol. Chem. 279: 34256-34268.
66. 2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem. Pharmacol. 61: 1153-1160.
67. Johnson, E. N., L. F. Brass, and C. D. Funk. 1998. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc. Natl. Acad. Sci. USA 95: 3100-3105. (Pubitemid 28135861)
68. Tang, K., and K. V. Honn. 1997. Lipoxygenase metabolites and cancer metastasis. Adv. Exp. Med. Biol. 422: 71-84.
69. Cyrus, T., J. L. Witztum, D. J. Rader, R. Tangirala, S. Fazio, M. F. Linton, and C. D. Funk. 1999. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103: 1597-1604.
70. Funk, C. D. 2006. Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26: 1204-1206.
71. Feinmark, S. J., R. Begum, E. Tsvetkov, I. Goussakov, C. D. Funk, S. A. Siegelbaum, and V. Y. Bolshakov. 2003. 12-Lipoxygenase metabolites of arachidonic acid mediate metabotropic glutamate receptor-dependent long-term depression at hippocampal CA3-CA1 synapses. J. Neurosci. 23: 11427-11435.
72. 2 and platelet-activating factor receptor in the Ca-induced biosynthesis of PAF. Biochem. Biophys. Res. Commun. 271: 812-817.
73. Kita, Y., T. Takahashi, N. Uozumi, L. Nallan, M. H. Gelb, and T. Shimizu. 2005. Pathway-oriented profiling of lipid mediators in macrophages. Biochem. Biophys. Res. Commun. 330: 898-906. (Pubitemid 40462171)
74. 2 in hypoxic pulmonary vasoconstriction. J. Clin. Invest. 109: 1493-1500.
75. Downey, P., A. Sapirstein, E. O'Leary, T. X. Sun, D. Brown, and J. V. Bonventre. 2001. Renal concentrating defect in mice lacking group IV cytosolic phospholipase A2. Am. J. Physiol. 280: F607-F618. (Pubitemid 32473258)
76. 2α is crucial for "on-time" embryo implantation that directs subsequent development. Development 129: 2879-2889.
77. 2αdeficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J. Clin. Invest. 118: 2121-2131.
78. 2β. J. Biol. Chem. 280: 24576-24583.
79. 2δ, induced in psoriatic skin. J. Biol. Chem. 279: 12890-12897.
80. 2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J. Exp. Med. 204: 865-877.
81. 2, in patients with suspected sepsis and organ failure. Crit. Care Med. 31: 718-728.
82. 2, fails to improve clinical outcome for patients with severe sepsis. Crit. Care Med. 33: 1741-1748.
83. Opal, S., P. F. Laterre, E. Abraham, B. Francois, X. Wittebole, S. Lowry, J. F. Dhainaut, B. Warren, T. Dugernier, A. Lopez, et al. 2004. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. 32: 332-341. (Pubitemid 38234108)